Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere Approved to Launch Myelosuppression-Prevention Drug in China

publication date: Jul 18, 2022

Simcere Pharma was conditionally approved to market Cosela® to reduce myelosuppression in patients who are treated with platinum/etoposide for extensive-stage small cell lung cancer. Cosela, a first-in-class drug, has a reversible CDK4/6 inhibitor that puts CDK4/6-dependent cells (hematopoietic stem and progenitor cells) into temporary arrest at the G1 phase of the cell cycle, reducing damage during chemotherapy. In 2020, Simcere in-licensed China rights to Cosela from G1 Therapeutics of North Carolina in a $170 million agreement. The drug was approved for US use last year. More details....

Stock Symbols: (HK: 02096) (NSDQ: GTHX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital